Canakinumab Halves Gout in Patients With Atherosclerosis Canakinumab Halves Gout in Patients With Atherosclerosis

However, the interleukin-1 inhibitor has no effect on serum urate, which is a risk marker for both gout and cardiovascular disease, a new analysis of data from CANTOS shows.Medscape Medical News

Source: Medscape Medical News Headlines - June 22, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news